Treatment advances in systemic juvenile idiopathic arthritis
- PMID: 24765526
- PMCID: PMC3974570
- DOI: 10.12703/P6-21
Treatment advances in systemic juvenile idiopathic arthritis
Abstract
Systemic juvenile idiopathic arthritis (JIA) is an autoinflammatory condition that is distinct from other forms of childhood arthritis. Recently, biologic agents that specifically inhibit the cytokines interleukin (IL)-1 and IL-6 have demonstrated remarkable clinical effectiveness and confirmed the importance of these cytokines in the disease process. Future studies are likely to optimize the care of children with systemic arthritis and further elucidate the disease pathogenesis.
References
-
- Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur A, Suarez-Almazor ME, Woo P. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2. - PubMed
-
- De Benedetti F, Schneider R. Systemic Juvenile Idiopathic Arthritis. In: Cassidy JT, Laxer RM, Petty RE, Lindsley CB, editors. Pediatric Rheumatology. 6. Philadelphia, PA: Saunders; 2011. - DOI
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
